Rahul Aggarwal, MD

Title(s)Professor, Medicine
SchoolSchool of Medicine
Address550 16th Street, #6546
San Francisco CA 94158
vCardDownload vCard

    Collapse Biography 
    Collapse education and training
    Northwestern University FeinbergM.D.2006School of Medicine
    University of California, San FranciscoResidency 2009School of Medicine - Internal Medicine
    University of California, San FranciscoFellowship2013Hematology/Oncology
    Collapse awards and honors
    2011  - 2012Pfizer Fellowship in Oncology
    2012  - 2013ASCO Young Investigator Award
    2013Alliance Cooperative Group Scholar Award
    2015  - 2017Prostate Cancer Foundation Young Investigator Award
    2016Department of Defense Prostate Cancer Program Physician Research Training Award
    2016  - 2019Department of Defense Prostate Cancer Program Idea Development Award
    National Cancer Institute2016  - 2017Cancer Clinical Investigator Team Leadership Award
    2021UCSF Division of Hematology & Oncology 2020 Marc A. Shuman Mentoring Award
    2022Prostate Cancer Foundation Challenge Award
    2024Thomas Perkins Distinguished Professor of Cancer Research

    Collapse Overview 
    Collapse overview
    I am a Medical Oncologist within the Division of Hematology/Oncology at the University of California San Francisco. My clinical practice focuses on patients with advanced solid tumor malignancies with a particular emphasis on genitourinary malignancies including prostate, kidney, bladder, and testicular cancer.

    I am the Program Leader for GU Medical Oncology program and Associate Director for Clinical Research in the UCSF Helen Diller Family Comprehensive Cancer Center.

    My research focus is on developing novel therapies and imaging modalities for patients with advanced solid tumor malignancies, with a focus on patients with advanced prostate cancer.
    Collapse media links

    Collapse Research 
    Collapse research activities and funding
    Precision targeting of T cell cytotoxicity with PET
    NIH R01CA258297Mar 1, 2021 - Feb 28, 2026
    Role: Co-Principal Investigator
    Measuring Metabolic Activity in Prostate Cancer Bone Metastases Using Hyperpolarized 13C Pyruvate MRI for Improved Targeted Therapy Monitoring
    NIH R01CA256740Dec 1, 2020 - Nov 30, 2025
    Role: Co-Principal Investigator
    Immunogenic Priming with Lu-PSMA Targeted Therapy in Advanced Prostate Cancer
    NIH R01CA229354Jun 1, 2019 - Apr 30, 2021
    Role: Principal Investigator
    Targeting Neuroendocrine Prostate Cancer Using Multi-Probe Hyperpolarized 13C MRI for Improved Treatment and Therapeutic Monitoring
    NIH R01CA215694Jun 1, 2017 - May 31, 2022
    Role: Co-Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Featured Publications

    Collapse Featured Content 
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. PROX1 is an early driver of lineage plasticity in prostate cancer. J Clin Invest. 2025 Jun 02; 135(11). Duan Z, Shi M, Kumaraswamy A, Lin D, Khokhani D, Wang Y, Zhang C, Flores D, Rodansky E, Swaim OA, Storck WK, Beck HN, Patel RA, Sayar E, Hanratty BP, Xue H, Dong X, Maylin ZR, Wan R, Quigley DA, Sjöström M, Hu YM, Zhao F, Xia Z, Cheng S, Yu X, Feng FY, Zhang L, Aggarwal R, Small EJ, Ravikumar V, Rao A, Bedi K, Lee JK, Morrissey C, Coleman I, Nelson PS, Corey E, Udager AM, Rebernick RJ, Cieslik MP, Chinnaiyan AM, Yates JA, Haffner MC, Wang Y, Alumkal JJ. PMID: 40454483.
      View in: PubMed   Mentions:
    2. Pre- or post-chemotherapy: effect on PSMA uptake. EJNMMI Res. 2025 Apr 07; 15(1):36. Yadav S, Tuchayi AM, Moradpour M, Jiang F, Juarez R, de Kouchkovsky I, Flavell RR, Aggarwal RR, Hope TA. PMID: 40192880; PMCID: PMC11977060.
      View in: PubMed   Mentions:
    3. NCCN Guidelines® Insights: Testicular Cancer, Version 2.2025. J Natl Compr Canc Netw. 2025 04; 23(4). Gilligan T, Lin DW, Adra N, Bagrodia A, Feldman DR, Yamoah K, Aggarwal R, Chandrasekar T, Costa D, Drakaki A, Eggener S, Emamekhoo H, Geynisman DM, Graham L, Humphrey P, Leuva H, Levine EG, Luckenbaugh A, Maughan BL, McGregor B, Monk P, Picus J, Pierorazio P, Rais-Bahrami S, Reichert Z, Rwigema JC, Saylor P, Shah A, Shah S, Singla N, Sircar K, VanderWeele D, Zhumkhawala A, Montgomery S, Sliker B. PMID: 40203876.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    4. Racial variation in the advanced prostate cancer genome. Prostate Cancer Prostatic Dis. 2025 Mar 31. Feng EM, Vo-Phamhi J, Subramanian AN, Dias M, Foye A, Vinson J, Hong JC, Freedland SJ, Alumkal JJ, Beltran H, Morrissey C, Nelson PS, Chinnaiyan AM, Aggarwal R, Small EJ, Quigley DA, Sjöström M, Zhao SG, Chen WS. PMID: 40164700.
      View in: PubMed   Mentions:    Fields:    
    5. Early changes of PSMA PET expression after initiation of androgen receptor signaling inhibitors in CRPC: an international multicenter retrospective study. Eur J Nucl Med Mol Imaging. 2025 Mar 26. Unterrainer LM, Farolfi A, Grogan T, Hotta M, Djaileb L, Gafita A, Sonni I, Rettig MB, Rosar F, Ezziddin S, Denis CS, de Kouchkovsky I, Aggarwal R, Emmett L, Hope TA, Czernin J, Calais J. PMID: 40137974.
      View in: PubMed   Mentions:    Fields:    
    6. Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients With Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2025 May 20; 43(15):1824-1834. Aggarwal RR, Vuky J, VanderWeele D, Rettig M, Heath EI, Quigley D, Huang J, Chumber A, Cheung A, Foye A, Leung S, Abbey J, Dorr A, Nasoff M, Hunter J, Wang S, Flavell RR, Fong L, Liu B, Small EJ. PMID: 40138611; PMCID: PMC12084135.
      View in: PubMed   Mentions: 1     Fields:    Translation:CTClinical Trials
    7. Emerging Therapeutic Targets of Neuroendocrine Prostate Cancer. Curr Oncol Rep. 2025 Apr; 27(4):362-374. Zhu X, Ding CC, Aggarwal RR. PMID: 40011325.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    8. Adverse prognosis gene expression patterns in metastatic castration-resistant prostate cancer. Mol Oncol. 2025 Feb 22. Sharifi MN, Feng E, Rydzewski NR, Taylor AK, Sperger JM, Shi Y, Helzer KT, Bootsma ML, Carreno V, Chang AH, Nunamaker LA, Blitzer GC, Shang TA, Subramanian A, Bjartell A, Josefsson A, Wikström P, Feng E, Kohli M, Yang R, Dehm SM, Small EJ, Aggarwal R, Quigley DA, Lang JM, Zhao SG, Sjöström M. PMID: 39985777.
      View in: PubMed   Mentions:    Fields:    
    9. Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized Trial. J Am Heart Assoc. 2025 Mar 04; 14(5):e038656. Aggarwal R, Bhatt DL, Steg PG, Miller M, Brinton EA, Dunbar RL, Ketchum SB, Tardif JC, Martens FMAC, Ballantyne CM, Szarek M, Mason RP, REDUCE-IT Investigators. PMID: 39968782; PMCID: PMC12132757.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    10. Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted 225Ac Therapy. Clin Cancer Res. 2025 Feb 13. Bidkar AP, Peter R, Wadhwa A, Bobba KN, Bidlingmaier S, Meher N, Chou J, Greenland N, Dasari C, Naik S, Raveendran A, Basak M, Camara Serrano JA, Steri V, Kogan S, Oskowitz A, He J, Wilson DM, Aggarwal R, Sriram R, VanBrocklin HF, Seo Y, Liu B, Flavell RR. PMID: 39945595.
      View in: PubMed   Mentions:    Fields:    
    11. Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies. Clin Cancer Res. 2025 Feb 03; 31(3):466-478. Haffner MC, Morris MJ, Ding CC, Sayar E, Mehra R, Robinson B, True LD, Gleave M, Lotan TL, Aggarwal R, Huang J, Loda M, Nelson PS, Rubin MA, Beltran H. PMID: 39589343; PMCID: PMC11790385.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    12. PET Imaging Using 89Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer. Mol Cancer Ther. 2025 Jan 02; 24(1):141-151. Meher N, Bidkar AP, Wadhwa A, Bobba KN, Dhrona S, Dasari C, Mu C, Fong COY, Cámara JA, Ali U, Basak M, Bulkley D, Steri V, Fontaine SD, Zhu J, Oskowitz A, Aggarwal RR, Sriram R, Chou J, Wilson DM, Seo Y, Santi DV, Ashley GW, VanBrocklin HF, Flavell RR. PMID: 39331510; PMCID: PMC11694059.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    13. Updated Survival Follow-Up for Phase Ib Trial of the Histone Deacetylase Inhibitor Abexinostat With Pazopanib in Patients With Solid Tumor Malignancies. JCO Precis Oncol. 2024 Nov; 8:e2400328. Tsang ES, Aggarwal RR, Bergsland EK, Calabrese S, Rozie A, Chaudhuri S, Dhawan MS, Pawlowska N, Grabowsky J, Thomas S, Munster PN. PMID: 39509670.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    14. Patients Can Administer Mobile Audio Recordings to Increase Knowledge in Advanced Prostate Cancer. Cancer Med. 2024 Nov; 13(22):e70433. Kwon DH, Trihy L, Darvish N, Hearst E, Sumra S, Borno HT, Bose R, Chou J, de Kouchkovsky I, Desai A, Ekstrand B, Friedlander T, Kaur G, Koshkin VS, Nesheiwat S, Sepucha K, Small EJ, Aggarwal RR, Belkora J. PMID: 39569542; PMCID: PMC11579662.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    15. An Atlas of Accessible Chromatin in Advanced Prostate Cancer Reveals the Epigenetic Evolution during Tumor Progression. Cancer Res. 2024 Sep 16; 84(18):3086-3100. Shrestha R, Chesner LN, Zhang M, Zhou S, Foye A, Lundberg A, Weinstein AS, Sjöström M, Zhu X, Moreno-Rodriguez T, Li H, SU2C/PCF West Coast Prostate Cancer Dream Team, Alumkal JJ, Aggarwal R, Small EJ, Lupien M, Quigley DA, Feng FY. PMID: 38990734.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    16. Impact of Posttreatment SPECT/CT on Patient Management During 177Lu-PSMA-617 Radiopharmaceutical Therapy. J Nucl Med. 2024 Sep 03; 65(9):1395-1401. Yadav S, Lowery B, Tuchayi AM, Jiang F, Saelee R, Aggarwal RR, Juarez R, Flavell RR, Hope TA. PMID: 39117452.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    17. Germline testing for veterans with advanced prostate cancer: concerns about service-connected benefits. JNCI Cancer Spectr. 2024 Sep 02; 8(5). Kwon DH, Scheuner MT, McPhaul M, Hearst E, Sumra S, Ursem C, Walker E, Wang S, Huang FW, Aggarwal RR, Belkora J. PMID: 39254645; PMCID: PMC11487480.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    18. Genomic and transcriptomic features of androgen receptor signaling inhibitor resistance in metastatic castration-resistant prostate cancer. J Clin Invest. 2024 Aug 13; 134(19). Zhu X, Farsh T, Vis D, Yu I, Li H, Liu T, Sjöström M, Shrestha R, Kneppers J, Severson T, Zhang M, Lundberg A, Moreno Rodriguez T, Weinstein AS, Foye A, Mehra N, Aggarwal RR, Bergman AM, Small EJ, Lack NA, Zwart W, Quigley DA, van der Heijden MS, Feng FY. PMID: 39352383; PMCID: PMC11444163.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    19. Integrated analyses highlight interactions between the three-dimensional genome and DNA, RNA and epigenomic alterations in metastatic prostate cancer. Nat Genet. 2024 Aug; 56(8):1689-1700. Zhao SG, Bootsma M, Zhou S, Shrestha R, Moreno-Rodriguez T, Lundberg A, Pan C, Arlidge C, Hawley JR, Foye A, Weinstein AS, Sjöström M, Zhang M, Li H, Chesner LN, Rydzewski NR, Helzer KT, Shi Y, West Coast Dream Team Consortium, Lynch M, Dehm SM, Lang JM, Alumkal JJ, He HH, Wyatt AW, Aggarwal R, Zwart W, Small EJ, Quigley DA, Lupien M, Feng FY. PMID: 39020220; PMCID: PMC11319208.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    20. Assessing Response to PSMA Radiopharmaceutical Therapies with Single SPECT Imaging at 24 Hours After Injection. J Nucl Med. 2024 Jul 01; 65(7):1064-1069. Yadav S, Jiang F, Kurkowska S, Saelee R, Morley A, Feng F, Aggarwal R, Lawhn-Heath C, Uribe C, Hope TA. PMID: 38724282.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    21. A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170). Cancer Res Commun. 2024 07 01; 4(7):1793-1801. Maldonado E, Rathmell WK, Shapiro GI, Takebe N, Rodon J, Mahalingam D, Trikalinos NA, Kalebasty AR, Parikh M, Boerner SA, Balido C, Krings G, Burns TF, Bergsland EK, Munster PN, Ashworth A, LoRusso P, Aggarwal RR. PMID: 38920407; PMCID: PMC11264598.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    22. Integrative analysis of ultra-deep RNA-seq reveals alternative promoter usage as a mechanism of activating oncogenic programmes during prostate cancer progression. Nat Cell Biol. 2024 Jul; 26(7):1176-1186. Zhang M, Sjöström M, Cui X, Foye A, Farh K, Shrestha R, Lundberg A, Dang HX, Li H, Febbo PG, Aggarwal R, Alumkal JJ, Small EJ, SU2C/PCF West Coast Prostate Cancer Dream Team, Maher CA, Feng FY, Quigley DA. PMID: 38871824; PMCID: PMC11844022.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    23. A prostate cancer gastrointestinal transcriptional phenotype may be associated with diminished response to AR-targeted therapy. bioRxiv. 2024 Jun 03. Subramanian A, Zhang M, Sharifi M, Moreno-Rodriguez T, Feng E, Rydzewski NR, Shrestha R, Zhu X, Zhao SG, Aggarwal R, Small EJ, Ding CC, Quigley DA, Sjöström M. PMID: 38895460; PMCID: PMC11185575.
      View in: PubMed   Mentions:
    24. 68Ga-FAP-2286 PET of Solid Tumors: Biodistribution, Dosimetry, and Comparison with 18F-FDG. J Nucl Med. 2024 Jun 03; 65(6):938-943. Kline B, Yadav S, Seo Y, Ippisch RC, Castillo J, Aggarwal RR, Kelley RK, Behr SC, Flavell RR, Lawhn-Heath C, Melisko M, Rugo HS, Wang V, Yom SS, Ha P, Jiang F, Hope TA. PMID: 38697672; PMCID: PMC11149593.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    25. Prostate-Specific Membrane Antigen Targeted StarPEG Nanocarrier for Imaging and Therapy of Prostate Cancer. Adv Healthc Mater. 2024 Jul; 13(19):e2304618. Meher N, Ashley GW, Bobba KN, Wadhwa A, Bidkar AP, Dasari C, Mu C, Sankaranarayanan RA, Serrano JAC, Raveendran A, Bulkley DP, Aggarwal R, Greenland NY, Oskowitz A, Wilson DM, Seo Y, Santi DV, VanBrocklin HF, Flavell RR. PMID: 38700450; PMCID: PMC11281871.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    26. Time to clinical benefit with sotagliflozin in patients with type 2 diabetes and chronic kidney disease: Insights from the SCORED randomized trial. Eur J Heart Fail. 2024 Apr; 26(4):1093-1095. Aggarwal R, Bhatt DL, Szarek M, Leiter LA, Cannon CP, Lopes RD, Davies MJ, Banks P, Pitt B, Steg PG. PMID: 38629597.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    27. Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer. Cancer Immunol Res. 2024 Apr 02; 12(4):453-461. Chang H, Marquez J, Chen BK, Kim DM, Cheng ML, Liu EV, Yang H, Zhang L, Sinha M, Cheung A, Kwek SS, Chow ED, Bridge M, Aggarwal RR, Friedlander TW, Small EJ, Anderson M, Fong L. PMID: 38276989; PMCID: PMC10993769.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    28. A Phase 1/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Prostate Cancer Prostatic Dis. 2025 Jun; 28(2):363-369. Wise DR, Pachynski RK, Denmeade SR, Aggarwal RR, Deng J, Febles VA, Balar AV, Economides MP, Loomis C, Selvaraj S, Haas M, Kagey MH, Newman W, Baum J, Troxel AB, Griglun S, Leis D, Yang N, Aranchiy V, Machado S, Waalkes E, Gargano G, Soamchand N, Puranik A, Chattopadhyay P, Fedal E, Deng FM, Ren Q, Chiriboga L, Melamed J, Sirard CA, Wong KK. PMID: 38341461.
      View in: PubMed   Mentions: 1     Fields:    Translation:CTClinical Trials
    29. Initial Experience with 68Ga-FAP-2286 PET Imaging in Patients with Urothelial Cancer. J Nucl Med. 2024 Feb 01; 65(2):199-205. Koshkin VS, Kumar V, Kline B, Escobar D, Aslam M, Cooperberg MR, Aggarwal RR, de Kouchkovsky I, Chou J, Meng MV, Friedlander T, Porten S, Hope TA. PMID: 38212070.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    30. Development of CD46 targeted alpha theranostics in prostate cancer using 134Ce/225Ac-Macropa-PEG4-YS5. Theranostics. 2024; 14(4):1344-1360. Bobba KN, Bidkar AP, Wadhwa A, Meher N, Drona S, Sorlin AM, Bidlingmaier S, Zhang L, Wilson DM, Chan E, Greenland NY, Aggarwal R, VanBrocklin HF, He J, Chou J, Seo Y, Liu B, Flavell RR. PMID: 38389832; PMCID: PMC10879874.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimals
    31. PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19). J Clin Oncol. 2024 Apr 01; 42(10):1114-1123. Aggarwal R, Heller G, Hillman DW, Xiao H, Picus J, Taplin ME, Dorff T, Appleman L, Weckstein D, Patnaik A, Bryce A, Shevrin D, Mohler J, Anderson D, Rao A, Tagawa S, Tan A, Halabi S, Dooley K, O'Brien P, Chen R, Ryan CJ, Eggener SE, Morris MJ, EORTC-55994 Study Group. PMID: 38261983; PMCID: PMC11637124.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    32. Diagnosis and management of neuroendocrine prostate cancer. Prostate. 2024 Apr; 84(5):426-440. de Kouchkovsky I, Chan E, Schloss C, Poehlein C, Aggarwal R. PMID: 38173302.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    33. Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial. Nat Commun. 2024 01 02; 15(1):14. Markowski MC, Taplin ME, Aggarwal R, Sena LA, Wang H, Qi H, Lalji A, Sinibaldi V, Carducci MA, Paller CJ, Marshall CH, Eisenberger MA, Sanin DE, Yegnasubramanian S, Gomes-Alexandre C, Ozbek B, Jones T, De Marzo AM, Denmeade SR, Antonarakis ES. PMID: 38167882; PMCID: PMC10762051.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    34. Biomarkers and novel PET imaging to detect neuroendocrine prostate cancer. Clin Adv Hematol Oncol. 2024 Jan-Feb; 22(1):16-17. Aggarwal R. PMID: 38294736.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    35. Oral Toxicities of PSMA-Targeted Immunotherapies for The Management of Prostate Cancer. Clin Genitourin Cancer. 2024 04; 22(2):380-384. Emperumal CP, Villa A, Hwang C, Oh D, Fong L, Aggarwal R, Keenan BP. PMID: 38185609.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    36. Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer. Eur Urol Oncol. 2024 Aug; 7(4):877-887. Orme JJ, Taza F, De Sarkar N, Tewari AK, Arsalan Naqvi S, Riaz IB, Childs DS, Omar N, Adra N, Ashkar R, Cheng HH, Schweizer MT, Sokolova AO, Agarwal N, Barata P, Sartor O, Bastos D, Smaletz O, Berchuck JE, McClure H, Taplin ME, Aggarwal R, Sternberg CN, Vlachostergios PJ, Alva AS, Mehra N, Nelson PS, Hwang J, Dehm SM, Shi Q, Fleischmann Z, Sokol ES, Elliott A, Huang H, Bryce A, Marshall CH, Antonarakis ES. PMID: 38072760; PMCID: PMC11162506.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    37. Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC). Br J Cancer. 2024 01; 130(1):53-62. Zhao JL, Antonarakis ES, Cheng HH, George DJ, Aggarwal R, Riedel E, Sumiyoshi T, Schonhoft JD, Anderson A, Mao N, Haywood S, Decker B, Curley T, Abida W, Feng FY, Knudsen K, Carver B, Lacouture ME, Wyatt AW, Rathkopf D. PMID: 37980367; PMCID: PMC10781677.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    38. Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial. Lancet Oncol. 2023 11; 24(11):1266-1276. Aggarwal R, Starzinski S, de Kouchkovsky I, Koshkin V, Bose R, Chou J, Desai A, Kwon D, Kaushal S, Trihy L, Rastogi M, Ippisch R, Aslam M, Friedlander T, Feng F, Oh D, Cheung A, Small E, Evans M, Fong L, Hope TA. PMID: 37922930; PMCID: PMC10667020.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    39. A case of cetuximab-induced radiation recall skin dermatitis and review of the literature. Radiat Oncol J. 2023 Dec; 41(4):292-296. Sabol RA, Patel AM, Sabbagh A, Wilson C, Yuen F, Lindenfeld P, Aggarwal R, Breyer B, Mohamad O. PMID: 38185934; PMCID: PMC10772596.
      View in: PubMed   Mentions:
    40. The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer. Cancer Res. 2023 08 15; 83(16):2763-2774. Lundberg A, Zhang M, Aggarwal R, Li H, Zhang L, Foye A, Sjöström M, Chou J, Chang K, Moreno-Rodriguez T, Shrestha R, Baskin A, Zhu X, Weinstein AS, Younger N, Alumkal JJ, Beer TM, Chi KN, Evans CP, Gleave M, Lara PN, Reiter RE, Rettig MB, Witte ON, Wyatt AW, Feng FY, Small EJ, Quigley DA. PMID: 37289025; PMCID: PMC10425725.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    41. Enrollment Barriers for Molecular Targeted Trials. JAMA Oncol. 2023 06 01; 9(6):863-864. Paydary K, DeLuca A, Aggarwal R, Wall L, Stadler WM. PMID: 37022722; PMCID: PMC10080401.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    42. Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas. Br J Cancer. 2023 08; 129(2):291-300. Raj N, Chan JA, Wang SJ, Aggarwal RR, Calabrese S, DeMore A, Fong L, Grabowsky J, Hope TA, Kolli KP, Mulvey CK, Munster PN, Perez K, Punn S, Reidy-Lagunes D, Von Fedak S, Zhang L, Bergsland EK. PMID: 37208512; PMCID: PMC10338510.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    43. Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab Vedotin. Clin Genitourin Cancer. 2023 10; 21(5):e394-e404. Jindal T, Zhang L, Deshmukh P, Reyes K, Chan E, Kumar V, Zhu X, Maldonado E, Feng S, Johnson M, Angelidakis A, Kwon D, Desai A, Borno HT, Bose R, Wong A, Hong J, Carroll P, Meng M, Porten S, Aggarwal R, Small EJ, Fong L, Chou J, Friedlander T, de Kouchkovsky I, Koshkin VS. PMID: 37316414.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    44. Treatment of Prostate Cancer with CD46-targeted 225Ac Alpha Particle Radioimmunotherapy. Clin Cancer Res. 2023 05 15; 29(10):1916-1928. Bidkar AP, Wang S, Bobba KN, Chan E, Bidlingmaier S, Egusa EA, Peter R, Ali U, Meher N, Wadhwa A, Dhrona S, Dasari C, Beckford-Vera D, Su Y, Tang R, Zhang L, He J, Wilson DM, Aggarwal R, VanBrocklin HF, Seo Y, Chou J, Liu B, Flavell RR. PMID: 36917693; PMCID: PMC10183825.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimals
    45. Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer. Front Oncol. 2023; 13:1161089. Jindal T, Zhu X, Bose R, Kumar V, Maldonado E, Deshmukh P, Shipp C, Feng S, Johnson MS, Angelidakis A, Kwon D, Borno HT, de Kouchkovsky I, Desai A, Aggarwal R, Fong L, Small EJ, Wong A, Porten S, Chou J, Friedlander T, Koshkin VS. PMID: 37091148; PMCID: PMC10113661.
      View in: PubMed   Mentions: 7  
    46. Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2023 06; 21(3):366-375. Lim EA, Schweizer MT, Chi KN, Aggarwal R, Agarwal N, Gulley J, Attiyeh E, Greger J, Wu S, Jaiprasart P, Loffredo J, Bandyopadhyay N, Xie H, Hansen AR. PMID: 36948922; PMCID: PMC10219845.
      View in: PubMed   Mentions: 17     Fields:    Translation:CTClinical Trials
    47. Intermittent Hormonal Therapy in Biochemical Recurrence of Prostate Cancer Is Worth Considering Because of Mitigation of Cardiovascular Events and Reduction of Other Effects. Eur Urol Focus. 2023 05; 9(3):405-406. Kwon DH, Aggarwal RR. PMID: 36690547.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    48. Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer. Cancer Res. 2023 01 18; 83(2):301-315. Chou J, Egusa EA, Wang S, Badura ML, Lee F, Bidkar AP, Zhu J, Shenoy T, Trepka K, Robinson TM, Steri V, Huang J, Wang Y, Small EJ, Chan E, Stohr BA, Ashworth A, Delafontaine B, Rottey S, Cooke KS, Hashemi Sadraei N, Yu B, Salvati M, Bailis JM, Feng FY, Flavell RR, Aggarwal R. PMID: 36351060; PMCID: PMC10263373.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansAnimals
    49. Implementation of a Telehealth Genetic Testing Station to Deliver Germline Testing for Men With Prostate Cancer. JCO Oncol Pract. 2023 05; 19(5):e773-e783. Kwon DH, Kwon DH, Gordon KM, Tong B, Borno HT, Beigh M, Fattah D, Schleicher A, Aggarwal RR, Blanco AM, Small EJ, Dhawan M. PMID: 36649492.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCellsPHPublic Health
    50. Quality of life for men with metastatic castrate-resistant prostate cancer participating in an aerobic and resistance exercise pilot intervention. Urol Oncol. 2023 03; 41(3):146.e1-146.e11. Langlais CS, Chen YH, Van Blarigan EL, Chan JM, Ryan CJ, Zhang L, Borno HT, Newton RU, Luke A, Bang AS, Panchal N, Tenggara I, Schultz B, Lavaki E, Pinto N, Aggarwal R, Friedlander T, Koshkin VS, Harzstark AL, Small EJ, Kenfield SA. PMID: 36528473.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    51. Intrinsic Molecular Subtypes of Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2022 12 15; 28(24):5396-5404. Feng E, Rydzewski NR, Zhang M, Lundberg A, Bootsma M, Helzer KT, Lang JM, Aggarwal R, Small EJ, Quigley DA, Sjöström M, Zhao SG. PMID: 36260524; PMCID: PMC9890931.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    52. Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracers. Urol Oncol. 2023 03; 41(3):145.e7-145.e15. Kwon DH, Shakhnazaryan N, Shui D, Hong JC, Mohamad O, de Kouchkovsky I, Borno HT, Bose R, Chou J, Desai A, Fong L, Friedlander TW, Koshkin VS, Aggarwal RR, Feng FY, Hope TA, Small EJ. PMID: 36435709.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    53. Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer. Prostate. 2023 02; 83(3):227-236. Su CT, Nizialek E, Berchuck JE, Vlachostergios PJ, Ashkar R, Sokolova A, Barata PC, Aggarwal RR, McKay RR, Agarwal N, McClure HM, Nafissi N, Bryce AH, Sartor O, Sayegh N, Cheng HH, Adra N, Sternberg CN, Taplin ME, Cieslik M, Alva AS, Antonarakis ES. PMID: 36382533; PMCID: PMC10099873.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    54. DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms. Oncologist. 2022 11 03; 27(11):940-951. Yao J, Bergsland E, Aggarwal R, Aparicio A, Beltran H, Crabtree JS, Hann CL, Ibrahim T, Byers LA, Sasano H, Umejiego J, Pavel M. PMID: 35983951; PMCID: PMC9632312.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    55. The 5-Hydroxymethylcytosine Landscape of Prostate Cancer. Cancer Res. 2022 11 02; 82(21):3888-3902. Sjöström M, Zhao SG, Levy S, Zhang M, Ning Y, Shrestha R, Lundberg A, Herberts C, Foye A, Aggarwal R, Hua JT, Li H, Bergamaschi A, Maurice-Dror C, Maheshwari A, Chen S, Ng SWS, Ye W, Petricca J, Fraser M, Chesner L, Perry MD, Moreno-Rodriguez T, Chen WS, Alumkal JJ, Chou J, Morgans AK, Beer TM, Thomas GV, Gleave M, Lloyd P, Phillips T, McCarthy E, Haffner MC, Zoubeidi A, Annala M, Reiter RE, Rettig MB, Witte ON, Fong L, Bose R, Huang FW, Luo J, Bjartell A, Lang JM, Mahajan NP, Lara PN, Evans CP, Tran PT, Posadas EM, He C, Cui XL, Huang J, Zwart W, Gilbert LA, Maher CA, Boutros PC, Chi KN, Ashworth A, Small EJ, He HH, Wyatt AW, Quigley DA, Feng FY. PMID: 36251389; PMCID: PMC9627125.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    56. Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer. Prostate Cancer. 2022; 2022:5454727. Aggarwal R, Alumkal JJ, Szmulewitz RZ, Higano CS, Bryce AH, Lopez-Gitlitz A, McCarthy SA, Miladinovic B, McQuarrie K, Thomas S, Zhang K, Small EJ. PMID: 36212187; PMCID: PMC9534720.
      View in: PubMed   Mentions: 3  
    57. Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity. Nat Commun. 2022 09 15; 13(1):5345. Westbrook TC, Guan X, Rodansky E, Flores D, Liu CJ, Udager AM, Patel RA, Haffner MC, Hu YM, Sun D, Beer TM, Foye A, Aggarwal R, Quigley DA, Youngren JF, Ryan CJ, Gleave M, Wang Y, Huang J, Coleman I, Morrissey C, Nelson PS, Evans CP, Lara P, Reiter RE, Witte O, Rettig M, Wong CK, Weinstein AS, Uzunangelov V, Stuart JM, Thomas GV, Feng FY, Small EJ, Yates JA, Xia Z, Alumkal JJ. PMID: 36109521; PMCID: PMC9477876.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    58. Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2022 09 15; 28(18):3979-3989. Aggarwal R, Starodub AN, Koh BD, Xing G, Armstrong AJ, Carducci MA. PMID: 35816286; PMCID: PMC9475238.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    59. Improving multiparametric MR-transrectal ultrasound guided fusion prostate biopsies with hyperpolarized 13 C pyruvate metabolic imaging: A technical development study. Magn Reson Med. 2022 Dec; 88(6):2609-2620. Chen HY, Bok RA, Cooperberg MR, Nguyen HG, Shinohara K, Westphalen AC, Wang ZJ, Ohliger MA, Gebrezgiabhier D, Carvajal L, Gordon JW, Larson PEZ, Aggarwal R, Kurhanewicz J, Vigneron DB. PMID: 35975978; PMCID: PMC9794017.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    60. Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer. Nature. 2022 08; 608(7921):199-208. Herberts C, Annala M, Sipola J, Ng SWS, Chen XE, Nurminen A, Korhonen OV, Munzur AD, Beja K, Schönlau E, Bernales CQ, Ritch E, Bacon JVW, Lack NA, Nykter M, Aggarwal R, Small EJ, Gleave ME, SU2C/PCF West Coast Prostate Cancer Dream Team, Quigley DA, Feng FY, Chi KN, Wyatt AW. PMID: 35859180.
      View in: PubMed   Mentions: 57     Fields:    Translation:HumansCells
    61. CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease. Clin Cancer Res. 2022 07 15; 28(14):3066-3075. Zhao N, Chopra S, Trepka K, Wang YH, Sakhamuri S, Hooshdaran N, Kim H, Zhou J, Lim SA, Leung KK, Egusa EA, Zhu J, Zhang L, Foye A, Sriram R, Chan E, Seo Y, Feng FY, Small EJ, Chou J, Wells JA, Aggarwal R, Evans MJ. PMID: 35604681; PMCID: PMC9288514.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimals
    62. A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies. Cancer Res Commun. 2022 07; 2(7):570-576. Tsang ES, Aggarwal RR, Dhawan MS, Bergsland EK, Alvarez EA, Calabrese S, Pacaud R, Garcia J, Fattah D, Thomas S, Grabowsky J, Moasser MM, Munster PN. PMID: 36923283; PMCID: PMC10010328.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    63. Skeletal-related events after abiraterone or enzalutamide in patients with metastatic castration-resistant prostate cancer: A population-based study using the SEER-Medicare linked dataset. Urol Oncol. 2022 08; 40(8):379.e17-379.e24. Kwon DH, Kwon DH, Paciorek A, Zhang L, Borno HT, Bucknor M, Small EJ, Aggarwal RR. PMID: 35750560.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    64. Mobile Clinical Trial Matching Technology in Medical Oncology Clinic: A Pilot Feasibility Study. JCO Clin Cancer Inform. 2022 05; 6:e2100182. Borno HT, Zhang L, Zhang S, Kaplan C, Palmer NR, Bell A, Bakke B, Lin A, Aggarwal R, Small EJ. PMID: 35584338; PMCID: PMC9173564.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    65. A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2022 04 14; 28(8):1531-1539. de Kouchkovsky I, Rao A, Carneiro BA, Zhang L, Lewis C, Phone A, Small EJ, Friedlander T, Fong L, Paris PL, Ryan CJ, Szmulewitz RZ, Aggarwal R. PMID: 35176163.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    66. APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial Cancer. Front Oncol. 2022; 12:816706. Natesan D, Zhang L, Martell HJ, Jindal T, Devine P, Stohr B, Espinosa-Mendez C, Grenert J, Van Ziffle J, Joseph N, Umetsu S, Onodera C, Turski M, Chan E, Desai A, Aggarwal R, Wong A, Porten S, Chou J, Friedlander T, Fong L, Small EJ, Sweet-Cordero A, Koshkin VS. PMID: 35321431; PMCID: PMC8935010.
      View in: PubMed   Mentions: 7  
    67. In Vivo Profiling with 18F-YJH08 Reveals Diverse Tissue Patterns of Antagonist/Glucocorticoid Receptor Interactions. Mol Pharm. 2022 02 07; 19(2):704-709. Kim H, Huang Y, Zhao N, Wang YH, Sakhamuri S, Chopra S, Hooshdaran N, Sriram R, Aggarwal R, Evans MJ. PMID: 35049307.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    68. The Emerging Role of Next-Generation Imaging in Prostate Cancer. Curr Oncol Rep. 2022 01; 24(1):33-42. Murthy V, Aggarwal R, Koo PJ. PMID: 35059998.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    69. Colchicine use in patients with COVID-19: A systematic review and meta-analysis. PLoS One. 2021; 16(12):e0261358. Chiu L, Lo CH, Shen M, Chiu N, Aggarwal R, Lee J, Choi YG, Lam H, Prsic EH, Chow R, Shin HJ. PMID: 34962939; PMCID: PMC8714120.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    70. Mobile Audio Recording Technology to Promote Informed Decision Making in Advanced Prostate Cancer. JCO Oncol Pract. 2022 05; 18(5):e648-e658. Kwon DH, Karthikeyan S, Chang A, Borno HT, Koshkin VS, Desai A, Bose R, Friedlander T, Rodvelt T, Li P, Small EJ, Aggarwal RR, Belkora J. PMID: 34932386.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    71. The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer. Nat Commun. 2021 12 21; 12(1):7349. Singh N, Ramnarine VR, Song JH, Pandey R, Padi SKR, Nouri M, Olive V, Kobelev M, Okumura K, McCarthy D, Hanna MM, Mukherjee P, Sun B, Lee BR, Parker JB, Chakravarti D, Warfel NA, Zhou M, Bearss JJ, Gibb EA, Alshalalfa M, Karnes RJ, Small EJ, Aggarwal R, Feng F, Wang Y, Buttyan R, Zoubeidi A, Rubin M, Gleave M, Slack FJ, Davicioni E, Beltran H, Collins C, Kraft AS. PMID: 34934057; PMCID: PMC8692330.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansAnimalsCells
    72. Hyperpolarized 1-[13C]-Pyruvate Magnetic Resonance Imaging Detects an Early Metabolic Response to Immune Checkpoint Inhibitor Therapy in Prostate Cancer. Eur Urol. 2022 02; 81(2):219-221. de Kouchkovsky I, Chen HY, Ohliger MA, Wang ZJ, Bok RA, Gordon JW, Larson PEZ, Frost M, Okamoto K, Cooperberg MR, Kurhanewicz J, Vigneron DB, Aggarwal R. PMID: 34758912; PMCID: PMC9275093.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    73. Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate Cancer. JAMA Oncol. 2021 Nov 01; 7(11):1644-1652. Aggarwal R, Rydzewski NR, Zhang L, Foye A, Kim W, Helzer KT, Bakhtiar H, Chang SL, Perry MD, Gleave M, Reiter RE, Huang J, Evans CP, Alumkal JJ, Lang JM, Yu M, Quigley DA, Sjöström M, Small EJ, Feng FY, Zhao SG. PMID: 34554200; PMCID: PMC8461554.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    74. Feasibility, safety, and acceptability of a remotely monitored exercise pilot CHAMP: A Clinical trial of High-intensity Aerobic and resistance exercise for Metastatic castrate-resistant Prostate cancer. Cancer Med. 2021 11; 10(22):8058-8070. Kenfield SA, Van Blarigan EL, Panchal N, Bang A, Zhang L, Graff RE, Chen YH, Ryan CJ, Luke A, Newton RU, Tenggara I, Schultz B, Wang E, Lavaki E, Zuniga K, Pinto N, Borno H, Aggarwal R, Friedlander T, Koshkin VS, Harzstark A, Small E, Chan JM. PMID: 34636156; PMCID: PMC8607248.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    75. Clinical translation of hyperpolarized 13 C pyruvate and urea MRI for simultaneous metabolic and perfusion imaging. Magn Reson Med. 2022 01; 87(1):138-149. Qin H, Tang S, Riselli AM, Bok RA, Delos Santos R, van Criekinge M, Gordon JW, Aggarwal R, Chen R, Goddard G, Zhang CT, Chen A, Reed G, Ruscitto DM, Slater J, Sriram R, Larson PEZ, Vigneron DB, Kurhanewicz J. PMID: 34374471; PMCID: PMC8616838.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    76. A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors. NPJ Precis Oncol. 2021 Aug 05; 5(1):74. Mansfield AS, Hong DS, Hann CL, Farago AF, Beltran H, Waqar SN, Hendifar AE, Anthony LB, Taylor MH, Bryce AH, Tagawa ST, Lewis K, Niu J, Chung CH, Cleary JM, Rossi M, Ludwig C, Valenzuela R, Luo Y, Aggarwal R. PMID: 34354225; PMCID: PMC8342450.
      View in: PubMed   Mentions: 34  
    77. A multidisciplinary team-based approach with lifestyle modification and symptom management to address the impact of androgen deprivation therapy in prostate cancer: A randomized phase II study. Urol Oncol. 2021 10; 39(10):730.e9-730.e15. Pollock Y, Zhang L, Kenfield SA, Van Blarigan EL, Rodvelt T, Rabow M, Macaire G, Weinberg R, Topp K, Friedlander T, Lin A, Fong L, Kim W, Ma B, Hough J, Lee M, Paciorek A, Ryan CJ, Chan JM, Small E, Aggarwal R. PMID: 34304981.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    78. Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer. JCO Precis Oncol. 2021; 5. Taza F, Holler AE, Fu W, Wang H, Adra N, Albany C, Ashkar R, Cheng HH, Sokolova AO, Agarwal N, Kessel A, Bryce A, Nafissi N, Barata P, Sartor AO, Bastos D, Smaletz O, Berchuck JE, Taplin ME, Aggarwal R, Sternberg CN, Vlachostergios PJ, Alva AS, Su C, Marshall CH, Antonarakis ES. PMID: 34778690; PMCID: PMC8575434.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    79. Specialized computational methods for denoising, B1 correction, and kinetic modeling in hyperpolarized 13 C MR EPSI studies of liver tumors. Magn Reson Med. 2021 11; 86(5):2402-2411. Lee PM, Chen HY, Gordon JW, Zhu Z, Larson PEZ, Dwork N, Van Criekinge M, Carvajal L, Ohliger MA, Wang ZJ, Xu D, Kurhanewicz J, Bok RA, Aggarwal R, Munster PN, Vigneron DB. PMID: 34216051; PMCID: PMC8565779.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    80. Prostate-specific membrane antigen (PSMA)-based imaging in localized and advanced prostate cancer: a narrative review. Transl Androl Urol. 2021 Jul; 10(7):3130-3143. de Kouchkovsky I, Aggarwal R, Hope TA. PMID: 34430416; PMCID: PMC8350242.
      View in: PubMed   Mentions: 5  
    81. BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program. Clin Cancer Res. 2021 09 01; 27(17):4923-4936. Kim DH, Sun D, Storck WK, Welker Leng K, Jenkins C, Coleman DJ, Sampson D, Guan X, Kumaraswamy A, Rodansky ES, Urrutia JA, Schwartzman JA, Zhang C, Beltran H, Labrecque MP, Morrissey C, Lucas JM, Coleman IM, Nelson PS, Corey E, Handelman SK, Sexton JZ, Aggarwal R, Abida W, Feng FY, Small EJ, Spratt DE, Bankhead A, Rao A, Gesner EM, Attwell S, Lakhotia S, Campeau E, Yates JA, Xia Z, Alumkal JJ. PMID: 34145028; PMCID: PMC8416959.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCells
    82. Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer. J Immunother Cancer. 2021 05; 9(5). Sinha M, Zhang L, Subudhi S, Chen B, Marquez J, Liu EV, Allaire K, Cheung A, Ng S, Nguyen C, Friedlander TW, Aggarwal R, Spitzer M, Allison JP, Small EJ, Sharma P, Fong L. PMID: 33986125; PMCID: PMC8126308.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCellsCTClinical Trials
    83. Cell-Free DNA Detection of Tumor Mutations in Heterogeneous, Localized Prostate Cancer Via Targeted, Multiregion Sequencing. JCO Precis Oncol. 2021; 5. Chen E, Cario CL, Leong L, Lopez K, Márquez CP, Li PS, Oropeza E, Tenggara I, Cowan J, Simko JP, Kageyama R, Wells DK, Chan JM, Friedlander T, Aggarwal R, Paris PL, Feng F, Carroll PR, Witte JS. PMID: 34250416; PMCID: PMC8232833.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    84. Differential treatment outcomes in BRCA1/2-, CDK12-, and ATM-mutated metastatic castration-resistant prostate cancer. Cancer. 2021 06 15; 127(12):1965-1973. Kwon DH, Chou J, Yip SM, Reimers MA, Zhang L, Wright F, Dhawan MS, Borno HT, Desai A, Aggarwal RR, Wyatt AW, Small EJ, Alva AS, Chi KN, Feng FY, Koshkin VS. PMID: 33690902.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    85. Cell-free DNA concentration and fragment size as a biomarker for prostate cancer. Sci Rep. 2021 03 03; 11(1):5040. Chen E, Cario CL, Leong L, Lopez K, Márquez CP, Chu C, Li PS, Oropeza E, Tenggara I, Cowan J, Simko JP, Chan JM, Friedlander T, Wyatt AW, Aggarwal R, Paris PL, Carroll PR, Feng F, Witte JS. PMID: 33658587; PMCID: PMC7930042.
      View in: PubMed   Mentions: 40     Fields:    Translation:Humans
    86. Resistance to Androgen Deprivation Leads to Altered Metabolism in Human and Murine Prostate Cancer Cell and Tumor Models. Metabolites. 2021 Feb 26; 11(3). Sun J, Bok RA, DeLos Santos J, Upadhyay D, DeLos Santos R, Agarwal S, Van Criekinge M, Vigneron DB, Aggarwal R, Peehl DM, Kurhanewicz J, Sriram R. PMID: 33652703; PMCID: PMC7996870.
      View in: PubMed   Mentions: 12  
    87. Androgen-deprivation therapy and SARS-CoV-2 in men with prostate cancer: findings from the University of California Health System registry. Ann Oncol. 2021 05; 32(5):678-679. Kwon DH, Vashisht R, Borno HT, Aggarwal RR, Small EJ, Butte AJ, Huang FW. PMID: 33571636; PMCID: PMC7870099.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    88. Large remodeling of the Myc-induced cell surface proteome in B cells and prostate cells creates new opportunities for immunotherapy. Proc Natl Acad Sci U S A. 2021 01 26; 118(4). Chen W, Mou KY, Solomon P, Aggarwal R, Leung KK, Wells JA. PMID: 33483421; PMCID: PMC7848737.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    89. Prime Time for Consultation Audio Recordings: Supporting Shared Decision Making During and After the COVID-19 Era. JCO Oncol Pract. 2021 04; 17(4):161-163. Kwon DH, Kwon DH, Aggarwal RR, Esserman LJ, Belkora JK. PMID: 33332174.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    90. Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET. Clin Cancer Res. 2021 03 01; 27(5):1305-1315. Wang S, Li J, Hua J, Su Y, Beckford-Vera DR, Zhao W, Jayaraman M, Huynh TL, Zhao N, Wang YH, Huang Y, Qin F, Shen S, Gioeli D, Dreicer R, Sriram R, Egusa EA, Chou J, Feng FY, Aggarwal R, Evans MJ, Seo Y, Liu B, Flavell RR, He J. PMID: 33293372; PMCID: PMC7925362.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansAnimalsCells
    91. Accelerating precision medicine in metastatic prostate cancer. Nat Cancer. 2020 11; 1(11):1041-1053. Mateo J, McKay R, Abida W, Aggarwal R, Alumkal J, Alva A, Feng F, Gao X, Graff J, Hussain M, Karzai F, Montgomery B, Oh W, Patel V, Rathkopf D, Rettig M, Schultz N, Smith M, Solit D, Sternberg C, Van Allen E, VanderWeele D, Vinson J, Soule HR, Chinnaiyan A, Small E, Simons JW, Dahut W, Miyahira AK, Beltran H. PMID: 34258585; PMCID: PMC8274325.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    92. Autoantibody Landscape in Patients with Advanced Prostate Cancer. Clin Cancer Res. 2020 12 01; 26(23):6204-6214. Chen WS, Haynes WA, Waitz R, Kamath K, Vega-Crespo A, Shrestha R, Zhang M, Foye A, Baselga Carretero I, Perez Garcilazo I, Zhang M, Zhao SG, Sjöström M, Quigley DA, Chou J, Beer TM, Rettig M, Gleave M, Evans CP, Lara P, Chi KN, Reiter RE, Alumkal JJ, Ashworth A, Aggarwal R, Small EJ, Daugherty PS, Ribas A, Oh DY, Shon JC, Feng FY. PMID: 32967941; PMCID: PMC7710628.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    93. The Synthesis and Structural Requirements for Measuring Glucocorticoid Receptor Expression In Vivo with (±)-11C-YJH08 PET. J Nucl Med. 2021 05 10; 62(5):723-731. Huang Y, Zhao N, Wang YH, Truillet C, Wei J, Parker MFL, Blecha JE, Drake CR, VanBrocklin HF, Garrido-Ruiz D, Jacobson MP, Aggarwal R, Behr SC, Flavell RR, Wilson DM, Seo Y, Evans MJ. PMID: 32887758; PMCID: PMC8844266.
      View in: PubMed   Mentions: 2     Fields:    Translation:AnimalsCells
    94. Dramatic response to combination pembrolizumab and radiation in metastatic castration resistant prostate cancer. Ther Adv Med Oncol. 2020; 12:1758835920936084. Han HJ, Li YR, Roach M, Aggarwal R. PMID: 32922519; PMCID: PMC7450451.
      View in: PubMed   Mentions: 19  
    95. Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2020 09 01; 26(17):4616-4624. Guan X, Sun D, Lu E, Urrutia JA, Reiter RE, Rettig M, Evans CP, Lara P, Gleave M, Beer TM, Thomas GV, Huang J, Aggarwal RR, Quigley DA, Foye A, Chen WS, Youngren J, Weinstein AS, Stuart JM, Feng FY, Small EJ, Xia Z, Alumkal JJ. PMID: 32727885; PMCID: PMC7484240.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    96. A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer. Clin Cancer Res. 2020 10 15; 26(20):5338-5347. Aggarwal RR, Schweizer MT, Nanus DM, Pantuck AJ, Heath EI, Campeau E, Attwell S, Norek K, Snyder M, Bauman L, Lakhotia S, Feng FY, Small EJ, Abida W, Alumkal JJ. PMID: 32694156; PMCID: PMC7572827.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansCTClinical Trials
    97. The DNA methylation landscape of advanced prostate cancer. Nat Genet. 2020 08; 52(8):778-789. Zhao SG, Chen WS, Li H, Foye A, Zhang M, Sjöström M, Aggarwal R, Playdle D, Liao A, Alumkal JJ, Das R, Chou J, Hua JT, Barnard TJ, Bailey AM, Chow ED, Perry MD, Dang HX, Yang R, Moussavi-Baygi R, Zhang L, Alshalalfa M, Laura Chang S, Houlahan KE, Shiah YJ, Beer TM, Thomas G, Chi KN, Gleave M, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Yvonne Kim M, Fong L, Spratt DE, Morgan TM, Bose R, Huang FW, Li H, Chesner L, Shenoy T, Goodarzi H, Asangani IA, Sandhu S, Lang JM, Mahajan NP, Lara PN, Evans CP, Febbo P, Batzoglou S, Knudsen KE, He HH, Huang J, Zwart W, Costello JF, Luo J, Tomlins SA, Wyatt AW, Dehm SM, Ashworth A, Gilbert LA, Boutros PC, Farh K, Chinnaiyan AM, Maher CA, Small EJ, Quigley DA, Feng FY. PMID: 32661416; PMCID: PMC7454228.
      View in: PubMed   Mentions: 161     Fields:    Translation:HumansCells
    98. Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancer. Urol Oncol. 2020 12; 38(12):931.e9-931.e16. Kwon DH, Zhang L, Quigley DA, Foye A, Chen WS, Wong CK, Feng FY, Bailey A, Huang J, Stuart JM, Friedl V, Weinstein AS, Beer TM, Alumkal JJ, Rettig M, Gleave M, Lara PN, Thomas GV, Li P, Lui A, Small EJ, Aggarwal RR. PMID: 32624423.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    99. Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer. Cancer. 2020 09 01; 126(17):3972-3981. Hanna GJ, Guenette JP, Chau NG, Sayehli CM, Wilhelm C, Metcalf R, Wong DJ, Brose M, Razaq M, Pérez-Ruiz E, Cohen EEW, Aggarwal R, Scholz C, Gualberto A, Ho AL. PMID: 32557577; PMCID: PMC8266417.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCTClinical Trials
    100. Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance. Proc Natl Acad Sci U S A. 2020 06 02; 117(22):12315-12323. Alumkal JJ, Sun D, Lu E, Beer TM, Thomas GV, Latour E, Aggarwal R, Cetnar J, Ryan CJ, Tabatabaei S, Bailey S, Turina CB, Quigley DA, Guan X, Foye A, Youngren JF, Urrutia J, Huang J, Weinstein AS, Friedl V, Rettig M, Reiter RE, Spratt DE, Gleave M, Evans CP, Stuart JM, Chen Y, Feng FY, Small EJ, Witte ON, Xia Z. PMID: 32424106; PMCID: PMC7275746.
      View in: PubMed   Mentions: 67     Fields:    Translation:HumansCTClinical Trials
    101. Emerging Subtypes and New Treatments for Castration-Resistant Prostate Cancer. Am Soc Clin Oncol Educ Book. 2020 May; 40:e319-e332. Carneiro BA, Lotan TL, de Souza A, Aggarwal R. PMID: 32479115.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    102. A Novel Radioligand Reveals Tissue Specific Pharmacological Modulation of Glucocorticoid Receptor Expression with Positron Emission Tomography. ACS Chem Biol. 2020 06 19; 15(6):1381-1391. Huang Y, Zhao N, Wang YH, Truillet C, Wei J, Blecha JE, VanBrocklin HF, Seo Y, Sayeed M, Feldman BJ, Aggarwal R, Behr SC, Shao H, Wilson DM, Villanueva-Meyer JE, Gestwicki JE, Evans MJ. PMID: 32255605; PMCID: PMC8031368.
      View in: PubMed   Mentions: 2     Fields:    Translation:Animals
    103. Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancer. Prostate Cancer Prostatic Dis. 2021 03; 24(1):81-87. Aggarwal R, Romero GR, Friedl V, Weinstein A, Foye A, Huang J, Feng F, Stuart JM, Small EJ. PMID: 32286548.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    104. Quantitative and Qualitative Improvement of Low-Count [68Ga]Citrate and [90Y]Microspheres PET Image Reconstructions Using Block Sequential Regularized Expectation Maximization Algorithm. Mol Imaging Biol. 2020 02; 22(1):208-216. Seo Y, Khalighi MM, Wangerin KA, Deller TW, Wang YH, Jivan S, Kohi MP, Aggarwal R, Flavell RR, Behr SC, Evans MJ. PMID: 30993558; PMCID: PMC6800603.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    105. Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019 12; 17(12):1529-1554. Gilligan T, Lin DW, Aggarwal R, Chism D, Cost N, Derweesh IH, Emamekhoo H, Feldman DR, Geynisman DM, Hancock SL, LaGrange C, Levine EG, Longo T, Lowrance W, McGregor B, Monk P, Picus J, Pierorazio P, Rais-Bahrami S, Saylor P, Sircar K, Smith DC, Tzou K, Vaena D, Vaughn D, Yamoah K, Yamzon J, Johnson-Chilla A, Keller J, Pluchino LA. PMID: 31805523.
      View in: PubMed   Mentions: 106     Fields:    Translation:Humans
    106. Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancer. Prostate Cancer Prostatic Dis. 2020 06; 23(2):316-323. Chen WS, Feng EL, Aggarwal R, Foye A, Beer TM, Alumkal JJ, Gleave M, Chi KN, Reiter RE, Rettig MB, Evans CP, Small EJ, Sharifi N, Zhao SG. PMID: 31745256; PMCID: PMC7529063.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    107. Improving research for prostate cancer survivorship: A statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group. Urol Oncol. 2020 03; 38(3):83-93. Narayan V, Harrison M, Cheng H, Kenfield S, Aggarwal R, Kwon D, McKay R, Hauger R, Hart N, Conzen S, Borno H, Jim H, Dicker A, Dorff T, Moslehi J, Mucci L, Parsons JK, Saad F, Soule H, Morgans A, Ryan CJ. PMID: 31734020.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    108. Hyperpolarized 13C-pyruvate MRI detects real-time metabolic flux in prostate cancer metastases to bone and liver: a clinical feasibility study. Prostate Cancer Prostatic Dis. 2020 06; 23(2):269-276. Chen HY, Aggarwal R, Bok RA, Ohliger MA, Zhu Z, Lee P, Gordon JW, van Criekinge M, Carvajal L, Slater JB, Larson PEZ, Small EJ, Kurhanewicz J, Vigneron DB. PMID: 31685983; PMCID: PMC7196510.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    109. Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2019 11; 76(5):562-571. Chen WS, Aggarwal R, Zhang L, Zhao SG, Thomas GV, Beer TM, Quigley DA, Foye A, Playdle D, Huang J, Lloyd P, Lu E, Sun D, Guan X, Rettig M, Gleave M, Evans CP, Youngren J, True L, Lara P, Kothari V, Xia Z, Chi KN, Reiter RE, Maher CA, Feng FY, Small EJ, Alumkal JJ, West Coast Prostate Cancer Dream Team. PMID: 30928160; PMCID: PMC6764911.
      View in: PubMed   Mentions: 64     Fields:    Translation:Humans
    110. Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity. Mol Cancer Res. 2019 06; 17(6):1235-1240. Aggarwal RR, Quigley DA, Huang J, Zhang L, Beer TM, Rettig MB, Reiter RE, Gleave ME, Thomas GV, Foye A, Playdle D, Lloyd P, Chi KN, Evans CP, Lara PN, Feng FY, Alumkal JJ, Small EJ. PMID: 30918106; PMCID: PMC6548614.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCells
    111. Systemic nature of spinal muscular atrophy revealed by studying insurance claims. PLoS One. 2019; 14(3):e0213680. Lipnick SL, Agniel DM, Aggarwal R, Makhortova NR, Finlayson SG, Brocato A, Palmer N, Darras BT, Kohane I, Rubin LL. PMID: 30870495; PMCID: PMC6417721.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    112. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer. BMC Cancer. 2019 Mar 04; 19(1):196. Mehnert JM, Varga A, Brose MS, Aggarwal RR, Lin CC, Prawira A, de Braud F, Tamura K, Doi T, Piha-Paul SA, Gilbert J, Saraf S, Thanigaimani P, Cheng JD, Keam B. PMID: 30832606; PMCID: PMC6399859.
      View in: PubMed   Mentions: 103     Fields:    Translation:HumansCTClinical Trials
    113. MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer. Prostate Cancer Prostatic Dis. 2019 12; 22(4):531-538. Nickols NG, Nazarian R, Zhao SG, Tan V, Uzunangelov V, Xia Z, Baertsch R, Neeman E, Gao AC, Thomas GV, Howard L, De Hoedt AM, Stuart J, Goldstein T, Chi K, Gleave ME, Graff JN, Beer TM, Drake JM, Evans CP, Aggarwal R, Foye A, Feng FY, Small EJ, Aronson WJ, Freedland SJ, Witte ON, Huang J, Alumkal JJ, Reiter RE, Rettig MB. PMID: 30804427; PMCID: PMC6853839.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansCells
    114. Coil combination methods for multi-channel hyperpolarized 13C imaging data from human studies. J Magn Reson. 2019 04; 301:73-79. Zhu Z, Zhu X, Ohliger MA, Tang S, Cao P, Carvajal L, Autry AW, Li Y, Kurhanewicz J, Chang S, Aggarwal R, Munster P, Xu D, Larson PEZ, Vigneron DB, Gordon JW. PMID: 30851668; PMCID: PMC7170546.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    115. Reply to A. Dalla Volta et al. J Clin Oncol. 2019 02 01; 37(4):351-352. Aggarwal R, Huang J, Alumkal J, Feng FY, Zhang L, Stuart JM, Small EJ. PMID: 30557523.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    116. Phase I Study of CTT1057, an 18F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer. J Nucl Med. 2019 07; 60(7):910-916. Behr SC, Aggarwal R, VanBrocklin HF, Flavell RR, Gao K, Small EJ, Blecha J, Jivan S, Hope TA, Simko JP, Kurhanewicz J, Noworolski SM, Korn NJ, De Los Santos R, Cooperberg MR, Carroll PR, Nguyen HG, Greene KL, Langton-Webster B, Berkman CE, Seo Y. PMID: 30464040; PMCID: PMC6604687.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    117. Translation of Carbon-13 EPI for hyperpolarized MR molecular imaging of prostate and brain cancer patients. Magn Reson Med. 2019 04; 81(4):2702-2709. Gordon JW, Chen HY, Autry A, Park I, Van Criekinge M, Mammoli D, Milshteyn E, Bok R, Xu D, Li Y, Aggarwal R, Chang S, Slater JB, Ferrone M, Nelson S, Kurhanewicz J, Larson PEZ, Vigneron DB. PMID: 30375043; PMCID: PMC6372313.
      View in: PubMed   Mentions: 48     Fields:    Translation:Humans
    118. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell. 2018 10 18; 175(3):889. Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY. PMID: 30340047.
      View in: PubMed   Mentions: 64     Fields:    
    119. Itraconazole as a Noncastrating Treatment for Biochemically Recurrent Prostate Cancer: A Phase 2 Study. Clin Genitourin Cancer. 2019 Feb; 17(1):e92-e96. Lee M, Hong H, Kim W, Zhang L, Friedlander TW, Fong L, Lin AM, Small EJ, Wei XX, Rodvelt TJ, Miralda B, Stocksdale B, Ryan CJ, Aggarwal R. PMID: 30327180.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    120. Investigation of analysis methods for hyperpolarized 13C-pyruvate metabolic MRI in prostate cancer patients. NMR Biomed. 2018 11; 31(11):e3997. Larson PEZ, Chen HY, Gordon JW, Korn N, Maidens J, Arcak M, Tang S, Criekinge M, Carvajal L, Mammoli D, Bok R, Aggarwal R, Ferrone M, Slater JB, Nelson SJ, Kurhanewicz J, Vigneron DB. PMID: 30230646; PMCID: PMC6392436.
      View in: PubMed   Mentions: 52     Fields:    Translation:Humans
    121. Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer. JCI Insight. 2018 09 06; 3(17). Su Y, Liu Y, Behrens CR, Bidlingmaier S, Lee NK, Aggarwal R, Sherbenou DW, Burlingame AL, Hann BC, Simko JP, Premasekharan G, Paris PL, Shuman MA, Seo Y, Small EJ, Liu B. PMID: 30185663; PMCID: PMC6171802.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansAnimalsCells
    122. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell. 2018 07 26; 174(3):758-769.e9. Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY. PMID: 30033370; PMCID: PMC6425931.
      View in: PubMed   Mentions: 312     Fields:    
    123. Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. J Clin Oncol. 2018 08 20; 36(24):2492-2503. Aggarwal R, Huang J, Alumkal JJ, Zhang L, Feng FY, Thomas GV, Weinstein AS, Friedl V, Zhang C, Witte ON, Lloyd P, Gleave M, Evans CP, Youngren J, Beer TM, Rettig M, Wong CK, True L, Foye A, Playdle D, Ryan CJ, Lara P, Chi KN, Uzunangelov V, Sokolov A, Newton Y, Beltran H, Demichelis F, Rubin MA, Stuart JM, Small EJ. PMID: 29985747; PMCID: PMC6366813.
      View in: PubMed   Mentions: 364     Fields:    Translation:HumansCellsCTClinical Trials
    124. Spatio-Temporally Constrained Reconstruction for Hyperpolarized Carbon-13 MRI Using Kinetic Models. IEEE Trans Med Imaging. 2018 12; 37(12):2603-2612. Maidens J, Gordon JW, Chen HY, Park I, Van Criekinge M, Milshteyn E, Bok R, Aggarwal R, Ferrone M, Slater JB, Kurhanewicz J, Vigneron DB, Arcak M, Larson PEZ. PMID: 29994332; PMCID: PMC6279499.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimals
    125. Development of an Algorithm to Identify Patients with Physician-Documented Insomnia. Sci Rep. 2018 05 18; 8(1):7862. Kartoun U, Aggarwal R, Beam AL, Pai JK, Chatterjee AK, Fitzgerald TP, Kohane IS, Shaw SY. PMID: 29777125; PMCID: PMC5959894.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    126. Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer. Eur Urol Oncol. 2018 05; 1(1):78-82. Aggarwal R, Wei X, Kim W, Small EJ, Ryan CJ, Carroll P, Cooperberg M, Evans MJ, Hope T. PMID: 31100231.
      View in: PubMed   Mentions: 44     Fields:    Translation:Humans
    127. Technique development of 3D dynamic CS-EPSI for hyperpolarized 13 C pyruvate MR molecular imaging of human prostate cancer. Magn Reson Med. 2018 11; 80(5):2062-2072. Chen HY, Larson PEZ, Gordon JW, Bok RA, Ferrone M, van Criekinge M, Carvajal L, Cao P, Pauly JM, Kerr AB, Park I, Slater JB, Nelson SJ, Munster PN, Aggarwal R, Kurhanewicz J, Vigneron DB. PMID: 29575178; PMCID: PMC6107425.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansAnimals
    128. A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone- and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate Cancer. Oncologist. 2018 06; 23(6):656-e64. Wei XX, Siegel AP, Aggarwal R, Lin AM, Friedlander TW, Fong L, Kim W, Louttit M, Chang E, Zhang L, Ryan CJ. PMID: 29487219; PMCID: PMC6067936.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    129. Defining the Prognostic and Predictive Impact of Germline DNA Repair Mutations in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2018 05; 73(5):694-695. Aggarwal R. PMID: 29458985.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    130. Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer. J Natl Cancer Inst. 2017 Dec 01; 109(12). Wyatt AW, Annala M, Aggarwal R, Beja K, Feng F, Youngren J, Foye A, Lloyd P, Nykter M, Beer TM, Alumkal JJ, Thomas GV, Reiter RE, Rettig MB, Evans CP, Gao AC, Chi KN, Small EJ, Gleave ME. PMID: 29206995; PMCID: PMC6440274.
      View in: PubMed   Mentions: 183     Fields:    Translation:HumansCells
    131. Abiraterone or Docetaxel Plus Androgen Deprivation in Hormone-Sensitive Prostate Cancer: More Questions Than Answers. Eur Urol. 2018 06; 73(6):845-846. Aggarwal R. PMID: 29128209.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    132. Moving toward a precision medicine approach in metastatic castration-resistant prostate cancer. Lancet Oncol. 2017 11; 18(11):1436-1437. Aggarwal R. PMID: 29033098.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    133. A Complete Metabolic Response of Metastatic Castration-resistant Neuroendocrine Carcinoma of the Prostate After Treatment with RRx-001 and Reintroduced Platinum Doublets. Eur Urol. 2018 02; 73(2):306-307. Brzezniak C, Oronsky B, Aggarwal R. PMID: 28943185.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    134. Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden. J Immunother Cancer. 2017 09 19; 5(1):75. Wang VE, Urisman A, Albacker L, Ali S, Miller V, Aggarwal R, Jablons D. PMID: 28923100; PMCID: PMC5604145.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    135. Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors. Breast Cancer Res. 2017 Sep 11; 19(1):107. Bartelink IH, Prideaux B, Krings G, Wilmes L, Lee PRE, Bo P, Hann B, Coppé JP, Heditsian D, Swigart-Brown L, Jones EF, Magnitsky S, Keizer RJ, de Vries N, Rosing H, Pawlowska N, Thomas S, Dhawan M, Aggarwal R, Munster PN, Esserman LJ, Ruan W, Wu AHB, Yee D, Dartois V, Savic RM, Wolf DM, van 't Veer L. PMID: 28893315; PMCID: PMC5594551.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    136. Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors. Clin Cancer Res. 2017 Nov 01; 23(21):6400-6410. Dhawan MS, Bartelink IH, Aggarwal RR, Leng J, Zhang JZ, Pawlowska N, Terranova-Barberio M, Grabowsky JA, Gewitz A, Chien AJ, Moasser M, Kelley RK, Maktabi T, Thomas S, Munster PN. PMID: 28790114.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCellsCTClinical Trials
    137. Hyperpolarized 1-[13C]-Pyruvate Magnetic Resonance Imaging Detects an Early Metabolic Response to Androgen Ablation Therapy in Prostate Cancer. Eur Urol. 2017 12; 72(6):1028-1029. Aggarwal R, Vigneron DB, Kurhanewicz J. PMID: 28765011; PMCID: PMC5723206.
      View in: PubMed   Mentions: 71     Fields:    Translation:Humans
    138. Emerging Categories of Disease in Advanced Prostate Cancer and Their Therapeutic Implications. Oncology (Williston Park). 2017 06 15; 31(6):467-74. Aggarwal RR, Feng FY, Small EJ. PMID: 28620903.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    139. Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer. Mol Cancer Res. 2017 09; 15(9):1221-1229. Aggarwal R, Behr SC, Paris PL, Truillet C, Parker MFL, Huynh LT, Wei J, Hann B, Youngren J, Huang J, Premasekharan G, Ranatunga N, Chang E, Gao KT, Ryan CJ, Small EJ, Evans MJ. PMID: 28592703; PMCID: PMC5581675.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    140. High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer. Clin Genitourin Cancer. 2017 12; 15(6):733-741.e1. Friedlander TW, Graff JN, Zejnullahu K, Anantharaman A, Zhang L, Paz R, Premasekharan G, Russell C, Huang Y, Kim W, Aggarwal RR, Lin AM, Fong L, Alumkal JJ, Beer TM, Sharifi N, Alyamani M, Dittamore R, Small EJ, Paris PL, Ryan CJ. PMID: 28655452.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    141. CT-Guided Bone Biopsies in Metastatic Castration-Resistant Prostate Cancer: Factors Predictive of Maximum Tumor Yield. J Vasc Interv Radiol. 2017 Aug; 28(8):1073-1081.e1. Holmes MG, Foss E, Joseph G, Foye A, Beckett B, Motamedi D, Youngren J, Thomas GV, Huang J, Aggarwal R, Alumkal JJ, Beer TM, Small EJ, Link TM. PMID: 28549709.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    142. Impact of 68Ga-PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer. J Nucl Med. 2017 12; 58(12):1956-1961. Hope TA, Aggarwal R, Chee B, Tao D, Greene KL, Cooperberg MR, Feng F, Chang A, Ryan CJ, Small EJ, Carroll PR. PMID: 28522741.
      View in: PubMed   Mentions: 61     Fields:    Translation:Humans
    143. Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors. Cancer Discov. 2017 09; 7(9):999-1005. Quigley D, Alumkal JJ, Wyatt AW, Kothari V, Foye A, Lloyd P, Aggarwal R, Kim W, Lu E, Schwartzman J, Beja K, Annala M, Das R, Diolaiti M, Pritchard C, Thomas G, Tomlins S, Knudsen K, Lord CJ, Ryan C, Youngren J, Beer TM, Ashworth A, Small EJ, Feng FY. PMID: 28450426; PMCID: PMC5581695.
      View in: PubMed   Mentions: 129     Fields:    
    144. Androgen receptor amplification is concordant between circulating tumor cells and biopsies from men undergoing treatment for metastatic castration resistant prostate cancer. Oncotarget. 2017 Sep 22; 8(42):71447-71455. Podolak J, Eilers K, Newby T, Slottke R, Tucker E, Olson SB, Lue HW, Youngren J, Aggarwal R, Small EJ, Graff JN, Alumkal JJ, Beer TM, Thomas GV. PMID: 29069718; PMCID: PMC5641061.
      View in: PubMed   Mentions: 14     Fields:    
    145. Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer. Eur Urol. 2017 07; 72(1):34-42. Annala M, Struss WJ, Warner EW, Beja K, Vandekerkhove G, Wong A, Khalaf D, Seppälä IL, So A, Lo G, Aggarwal R, Small EJ, Nykter M, Gleave ME, Chi KN, Wyatt AW. PMID: 28259476.
      View in: PubMed   Mentions: 99     Fields:    Translation:HumansCells
    146. Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies. J Clin Oncol. 2017 Apr 10; 35(11):1231-1239. Aggarwal R, Thomas S, Pawlowska N, Bartelink I, Grabowsky J, Jahan T, Cripps A, Harb A, Leng J, Reinert A, Mastroserio I, Truong TG, Ryan CJ, Munster PN. PMID: 28221861; PMCID: PMC5791833.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansCellsCTClinical Trials
    147. A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study. Urol Oncol. 2017 04; 35(4):149.e7-149.e13. Aggarwal R, Bryce A, Ryan CJ, Harzstark A, Derleth C, Kim W, Friedlander T, Lin AM, Rodvelt-Bagchi T, Dhawan M, Zhang L, Lee M, Siebeneck E, Hough J, Small EJ. PMID: 28161323.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    148. Imaging Hepatocellular Carcinoma With 68Ga-Citrate PET: First Clinical Experience. Mol Imaging. 2017 Jan-Dec; 16:1536012117723256. Mari Aparici C, Behr SC, Seo Y, Kelley RK, Corvera C, Gao KT, Aggarwal R, Evans MJ. PMID: 28893116; PMCID: PMC5598799.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    149. A Feasibility Study Showing [68Ga]Citrate PET Detects Prostate Cancer. Mol Imaging Biol. 2016 12; 18(6):946-951. Behr SC, Aggarwal R, Seo Y, Aparici CM, Chang E, Gao KT, Tao DH, Small EJ, Evans MJ. PMID: 27184068; PMCID: PMC6430569.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    150. Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer: Update on the Stand Up 2 Cancer/Prostate Cancer Foundation-Supported West Coast Prostate Cancer Dream Team. Eur Urol Focus. 2016 Dec; 2(5):469-471. Aggarwal R, Beer TM, Gleave M, Stuart JM, Rettig M, Evans CP, Youngren J, Alumkal JJ, Huang J, Thomas G, Witte O, Small EJ. PMID: 28723508.
      View in: PubMed   Mentions: 7     Fields:    
    151. 68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience. J Nucl Med. 2017 Jan; 58(1):81-84. Hope TA, Truillet C, Ehman EC, Afshar-Oromieh A, Aggarwal R, Ryan CJ, Carroll PR, Small EJ, Evans MJ. PMID: 27660139; PMCID: PMC5209643.
      View in: PubMed   Mentions: 103     Fields:    Translation:HumansAnimalsCells
    152. Targeted PET imaging for prostate-specific membrane antigen in prostate cancer. Future Oncol. 2016 Nov; 12(21):2393-2396. Hope TA, Aggarwal RR, Westphalen AC, Cooperberg MR, Greene KL. PMID: 27453303.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    153. Prednisone Use in Conjunction with Abiraterone Acetate: Is Patient Safety a Concern with Long-term Steroid Exposure? Eur Urol. 2016 09; 70(3):445-6. Aggarwal R. PMID: 26992281.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    154. Approaches to minimize castration in the treatment of advanced prostate cancer. Urol Oncol. 2016 08; 34(8):368-74. Zejnullahu K, Arevalo MG, Ryan CJ, Aggarwal R. PMID: 26944450.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    155. A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma. Ann Oncol. 2016 05; 27(5):947-52. Thomas S, Aggarwal R, Jahan T, Ryan C, Troung T, Cripps AM, Raha P, Thurn KT, Chen S, Grabowsky JA, Park J, Hwang J, Daud A, Munster PN. PMID: 26903311; PMCID: PMC4843187.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCellsCTClinical Trials
    156. First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies. Clin Cancer Res. 2016 Apr 15; 22(8):1932-9. Munster P, Aggarwal R, Hong D, Schellens JH, van der Noll R, Specht J, Witteveen PO, Werner TL, Dees EC, Bergsland E, Agarwal N, Kleha JF, Durante M, Adams L, Smith DA, Lampkin TA, Morris SR, Kurzrock R. PMID: 26603258.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansCTClinical Trials
    157. Somatostatin imaging of neuroendocrine-differentiated prostate cancer. Clin Nucl Med. 2015 Jun; 40(6):540-1. Hope TA, Aggarwal R, Simko JP, VanBrocklin HF, Ryan CJ. PMID: 25783510.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    158. Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF. Clin Genitourin Cancer. 2015 Jun; 13(3):e191-8. Aggarwal RR, Beer TM, Weinberg VK, Higano C, Taplin ME, Ryan CJ, Lin AM, Alumkal J, Graff JN, Nordquist LT, Herrera I, Small EJ. PMID: 25557266.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    159. Small-cell/neuroendocrine prostate cancer: a growing threat? Oncology (Williston Park). 2014 Oct; 28(10):838-40. Aggarwal RR, Small EJ. PMID: 25323608.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    160. Impact of patient ethnicity on the metabolic and immunologic effects of PI3K-mTOR pathway inhibition in patients with solid tumor malignancies. Cancer Chemother Pharmacol. 2014 Aug; 74(2):359-65. Aggarwal R, Grabowsky J, Strait N, Cockerill A, Munster P. PMID: 24934865; PMCID: PMC5257275.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    161. Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes. J Natl Compr Canc Netw. 2014 May; 12(5):719-26. Aggarwal R, Zhang T, Small EJ, Armstrong AJ. PMID: 24812138.
      View in: PubMed   Mentions: 88     Fields:    Translation:Humans
    162. Response to subsequent docetaxel in a patient cohort with metastatic castration-resistant prostate cancer after abiraterone acetate treatment. Clin Genitourin Cancer. 2014 Oct; 12(5):e167-72. Aggarwal R, Harris A, Formaker C, Small EJ, Molina A, Griffin TW, Ryan CJ. PMID: 24787968.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    163. The changing role of imaging in clinical care. Nat Rev Urol. 2014 Feb; 11(2):75-7. Aggarwal R, Kurhanewicz J. PMID: 24418808; PMCID: PMC4057014.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    164. The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance). Cancer. 2013 Oct 15; 119(20):3636-43. Aggarwal R, Halabi S, Kelly WK, George D, Mahoney JF, Millard F, Stadler WM, Morris MJ, Kantoff P, Monk JP, Carducci M, Small EJ, Alliance for Clinical Trials in Oncology. PMID: 23913744; PMCID: PMC3795898.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    165. Insulin-like growth factor pathway: a link between androgen deprivation therapy (ADT), insulin resistance, and disease progression in patients with prostate cancer? Urol Oncol. 2013 Jul; 31(5):522-30. Aggarwal RR, Ryan CJ, Chan JM. PMID: 21658978.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    166. Castration-resistant prostate cancer: targeted therapies and individualized treatment. Oncologist. 2011; 16(3):264-75. Aggarwal R, Ryan CJ. PMID: 21339259; PMCID: PMC3228103.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    167. The mechanism of action of estrogen in castration-resistant prostate cancer: clues from hormone levels. Clin Genitourin Cancer. 2009 Oct; 7(3):E71-6. Aggarwal R, Weinberg V, Small EJ, Oh W, Rushakoff R, Ryan CJ. PMID: 19815485.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    Rahul's Networks
    Concepts (479)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (182)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-15-g9ae42700 on PROFILES-PWEB04.

    Copyright © The Regents of the University of California.